Denosumab  ||| S:0 E:10 ||| NNP
for  ||| S:10 E:14 ||| IN
the  ||| S:14 E:18 ||| DT
prevention  ||| S:18 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
osteoporotic  ||| S:32 E:45 ||| JJ
fractures  ||| S:45 E:55 ||| NN
in  ||| S:55 E:58 ||| IN
postmenopausal  ||| S:58 E:73 ||| JJ
women  ||| S:73 E:79 ||| NNS
This  ||| S:79 E:84 ||| DT
paper  ||| S:84 E:90 ||| NN
presents  ||| S:90 E:99 ||| VBZ
a  ||| S:99 E:101 ||| DT
summary  ||| S:101 E:109 ||| NN
of  ||| S:109 E:112 ||| IN
the  ||| S:112 E:116 ||| DT
evidence  ||| S:116 E:125 ||| NN
review  ||| S:125 E:132 ||| NN
group  ||| S:132 E:138 ||| NN
( ||| S:138 E:139 ||| -LRB-
ERG ||| S:139 E:142 ||| NNP
)  ||| S:142 E:144 ||| -RRB-
report  ||| S:144 E:151 ||| NN
into  ||| S:151 E:156 ||| IN
denosumab  ||| S:156 E:166 ||| NN
for  ||| S:166 E:170 ||| IN
the  ||| S:170 E:174 ||| DT
prevention  ||| S:174 E:185 ||| NN
of  ||| S:185 E:188 ||| IN
osteoporotic  ||| S:188 E:201 ||| JJ
fractures  ||| S:201 E:211 ||| NN
in  ||| S:211 E:214 ||| IN
postmenopausal  ||| S:214 E:229 ||| JJ
women ||| S:229 E:234 ||| NNS
.  ||| S:234 E:236 ||| .
Denosumab  ||| S:236 E:246 ||| NNP
has  ||| S:246 E:250 ||| VBZ
been  ||| S:250 E:255 ||| VBN
shown  ||| S:255 E:261 ||| VBN
in  ||| S:261 E:264 ||| IN
a  ||| S:264 E:266 ||| DT
large  ||| S:266 E:272 ||| JJ
randomised  ||| S:272 E:283 ||| JJ
trial  ||| S:283 E:289 ||| NN
to  ||| S:289 E:292 ||| TO
reduce  ||| S:292 E:299 ||| VB
the  ||| S:299 E:303 ||| DT
frequency  ||| S:303 E:313 ||| NN
of  ||| S:313 E:316 ||| IN
osteoporotic  ||| S:316 E:329 ||| JJ
fractures  ||| S:329 E:339 ||| NN
when  ||| S:339 E:344 ||| WRB
given  ||| S:344 E:350 ||| VBN
subcutaneously  ||| S:350 E:365 ||| VBN
at  ||| S:365 E:368 ||| IN
6-monthly  ||| S:368 E:378 ||| CD
intervals ||| S:378 E:387 ||| NNS
.  ||| S:387 E:389 ||| .
Compared  ||| S:389 E:398 ||| VBN
with  ||| S:398 E:403 ||| IN
placebo ||| S:403 E:410 ||| NN
,  ||| S:410 E:412 ||| ,
the  ||| S:412 E:416 ||| DT
relative  ||| S:416 E:425 ||| JJ
risks  ||| S:425 E:431 ||| NNS
of  ||| S:431 E:434 ||| IN
clinical  ||| S:434 E:443 ||| JJ
vertebral  ||| S:443 E:453 ||| NN
and  ||| S:453 E:457 ||| CC
hip  ||| S:457 E:461 ||| JJ
fractures  ||| S:461 E:471 ||| NN
were  ||| S:471 E:476 ||| VBD
0.32  ||| S:476 E:481 ||| CD
and  ||| S:481 E:485 ||| CC
0.60 ||| S:485 E:489 ||| CD
,  ||| S:489 E:491 ||| ,
respectively ||| S:491 E:503 ||| RB
.  ||| S:503 E:505 ||| .
Clinical  ||| S:505 E:514 ||| JJ
vertebral  ||| S:514 E:524 ||| NNS
fractures  ||| S:524 E:534 ||| VBP
occurred  ||| S:534 E:543 ||| VBN
in  ||| S:543 E:546 ||| IN
0.8 ||| S:546 E:549 ||| CD
%  ||| S:549 E:551 ||| NN
of  ||| S:551 E:554 ||| IN
women  ||| S:554 E:560 ||| NNS
taking  ||| S:560 E:567 ||| VBG
denosumab  ||| S:567 E:577 ||| NNS
and  ||| S:577 E:581 ||| CC
2.6 ||| S:581 E:584 ||| CD
%  ||| S:584 E:586 ||| NN
of  ||| S:586 E:589 ||| IN
control  ||| S:589 E:597 ||| NN
subjects ||| S:597 E:605 ||| NNS
.  ||| S:605 E:607 ||| .
Hip  ||| S:607 E:611 ||| NNP
fractures  ||| S:611 E:621 ||| VBD
occurred  ||| S:621 E:630 ||| VBN
in  ||| S:630 E:633 ||| IN
1.2 ||| S:633 E:636 ||| CD
%  ||| S:636 E:638 ||| NN
of  ||| S:638 E:641 ||| IN
women  ||| S:641 E:647 ||| NNS
on  ||| S:647 E:650 ||| IN
placebo  ||| S:650 E:658 ||| NN
and  ||| S:658 E:662 ||| CC
0.7 ||| S:662 E:665 ||| CD
%  ||| S:665 E:667 ||| NN
on  ||| S:667 E:670 ||| IN
denosumab ||| S:670 E:679 ||| NN
.  ||| S:679 E:681 ||| .
The  ||| S:681 E:685 ||| DT
expected  ||| S:685 E:694 ||| JJ
use  ||| S:694 E:698 ||| NN
is  ||| S:698 E:701 ||| VBZ
in  ||| S:701 E:704 ||| IN
women  ||| S:704 E:710 ||| NNS
who  ||| S:710 E:714 ||| WP
cannot  ||| S:714 E:721 ||| RB
tolerate  ||| S:721 E:730 ||| VB
oral  ||| S:730 E:735 ||| JJ
bisphosphonates ||| S:735 E:750 ||| NN
.  ||| S:750 E:752 ||| .
Other  ||| S:752 E:758 ||| JJ
options  ||| S:758 E:766 ||| NNS
in  ||| S:766 E:769 ||| IN
that  ||| S:769 E:774 ||| DT
situation  ||| S:774 E:784 ||| NN
include  ||| S:784 E:792 ||| VBP
strontium  ||| S:792 E:802 ||| JJ
ranelate  ||| S:802 E:811 ||| NN
and  ||| S:811 E:815 ||| CC
zoledronate ||| S:815 E:826 ||| NN
,  ||| S:826 E:828 ||| ,
which ||| S:828 E:833 ||| WDT
,  ||| S:833 E:835 ||| ,
compared  ||| S:835 E:844 ||| VBN
with  ||| S:844 E:849 ||| IN
placebo ||| S:849 E:856 ||| NN
,  ||| S:856 E:858 ||| ,
also  ||| S:858 E:863 ||| RB
reduced  ||| S:863 E:871 ||| VBN
the  ||| S:871 E:875 ||| DT
risk  ||| S:875 E:880 ||| NN
of  ||| S:880 E:883 ||| IN
clinical  ||| S:883 E:892 ||| JJ
vertebral  ||| S:892 E:902 ||| JJ
fractures  ||| S:902 E:912 ||| NNS
[ ||| S:912 E:913 ||| -LRB-
relative  ||| S:913 E:922 ||| JJ
risk  ||| S:922 E:927 ||| NN
( ||| S:927 E:928 ||| -LRB-
RR ||| S:928 E:930 ||| NNP
)  ||| S:930 E:932 ||| -RRB-
0.65  ||| S:932 E:937 ||| NNP
and  ||| S:937 E:941 ||| CC
0.23 ||| S:941 E:945 ||| CD
,  ||| S:945 E:947 ||| ,
respectively ||| S:947 E:959 ||| RB
] ||| S:959 E:960 ||| -RRB-
.  ||| S:960 E:962 ||| .
Zoledronate  ||| S:962 E:974 ||| NNP
also  ||| S:974 E:979 ||| RB
significantly  ||| S:979 E:993 ||| RB
reduced  ||| S:993 E:1001 ||| VBN
the  ||| S:1001 E:1005 ||| DT
risk  ||| S:1005 E:1010 ||| NN
of  ||| S:1010 E:1013 ||| IN
hip  ||| S:1013 E:1017 ||| JJ
fractures  ||| S:1017 E:1027 ||| NNS
( ||| S:1027 E:1028 ||| -LRB-
RR  ||| S:1028 E:1031 ||| NNP
0.59 ||| S:1031 E:1035 ||| CD
) ||| S:1035 E:1036 ||| -RRB-
.  ||| S:1036 E:1038 ||| .
The  ||| S:1038 E:1042 ||| DT
ERG  ||| S:1042 E:1046 ||| NNP
concluded  ||| S:1046 E:1056 ||| VBD
that  ||| S:1056 E:1061 ||| DT
zoledronate  ||| S:1061 E:1073 ||| NN
was  ||| S:1073 E:1077 ||| VBD
the  ||| S:1077 E:1081 ||| DT
main  ||| S:1081 E:1086 ||| JJ
comparator ||| S:1086 E:1096 ||| NN
.  ||| S:1096 E:1098 ||| .
The  ||| S:1098 E:1102 ||| DT
relative  ||| S:1102 E:1111 ||| JJ
cost-effectiveness  ||| S:1111 E:1130 ||| NN
of  ||| S:1130 E:1133 ||| IN
denosumab  ||| S:1133 E:1143 ||| NN
and  ||| S:1143 E:1147 ||| CC
zoledronate  ||| S:1147 E:1159 ||| NN
depends  ||| S:1159 E:1167 ||| VBZ
mainly  ||| S:1167 E:1174 ||| RB
on  ||| S:1174 E:1177 ||| IN
assumptions  ||| S:1177 E:1189 ||| NNS
about  ||| S:1189 E:1195 ||| IN
costs  ||| S:1195 E:1201 ||| NNS
of  ||| S:1201 E:1204 ||| IN
administration ||| S:1204 E:1218 ||| NN
.  ||| S:1218 E:1220 ||| .
